Navigation Links
Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
Date:5/19/2008

Superiority of Ablation Therapy Using HALO System Demonstrated for Eradicating Barrett's Esophagus and Reducing Risk for Disease Progression

SAN DIEGO, May 19 /PRNewswire/ -- Booth #2349 -- Digestive Disease Week -- BARRX Medical, Inc., a technology leader in the design and manufacture of medical devices for digestive diseases, today announced the presentation of a landmark study entitled, "A Randomized, Multicenter, Sham-Controlled Trial of Radiofrequency Ablation (RFA) for Subjects with Barrett's Esophagus (BE) Containing Dysplasia: Interim Results of the AIM Dysplasia Trial." The study was presented by Nicholas J. Shaheen, M.D., Associate Professor of Medicine and Epidemiology, The University of North Carolina, during the clinical plenary session of the American Gastroenterological Association at the Digestive Disease Week meeting in San Diego, California.

"This is a very well-designed trial conducted in a rigorous manner at 19 expert U.S. centers, each having experience in the management of Barrett's esophagus and dysplasia," said Dr. Shaheen. "Our interim results are highly promising, demonstrating superiority for ablation therapy for eliminating Barrett's and dysplasia, as well as reducing the risk for disease progression. Although we continue to complete the trial, these results may ultimately change the paradigm for how gastroenterologists manage their patients with Barrett's esophagus."

Beginning in 2006, the AIM Dysplasia Trial enrolled 127 patients with a diagnosis of dysplastic Barrett's esophagus, the most advanced stage of this precancerous condition. As a result of injury from gastroesophageal reflux disease or GERD, the normal esophageal lining is replaced with abnormal cells (Barrett's tissue), predisposing the patient to a higher risk for developing cancer of the esophagus. Patients with Barrett's who develop cancer, typically do so through a series of steps, starting with Barrett's, then Barrett's with low-grade dyspl
'/>"/>

SOURCE BARRX Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
2. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
3. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
4. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
5. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Notice of Time Change for Alexions Presentation at the Bank of America 2008 Health Care Conference
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
9. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
10. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
11. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Local veterinary ... in an investigational study of donor stem cells for ... stem cell therapy and has performed clinical stem cell ... study is to determine if a single injection of ... joints can help reduce pain and inflammation in the ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... , - Company Also Granted Expansion of Prophylaxis Therapy Label ... , EXTON, Pa., June 4 ViroPharma Incorporated (Nasdaq: ... Complete Response letter from the U.S. Food and Drug Administration ... Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute ...
... SYDNEY, June 3 /PRNewswire-Asia/ -- Pharmaxis (ASX: ... had raised A$47 million through a placement to,Australian and ... company,s balance sheet as Pharmaxis moves toward,the European and ... , Pharmaxis will issue 20 ...
... 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of Sangamo,s ZFP Therapeutic(TM) ... at 11:30 am ET on Wednesday, June 10, 2009 at ... held in New York City. , , The presentation ...
Cached Biology Technology:ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 2ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 3ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 4ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 5Pharmaxis Announces Placement of $47 Million and Share Purchase Plan 2Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference 2
(Date:10/15/2014)... PORT WASHINGTON, N.Y. , Oct. 15, 2014 ... in technology solutions for home and community-based care, ... the benefits of implementing Sandata,s Santrax® Electronic Visit ... Quality Care Services is a home health company ... Texas . ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... is hot on the research agenda. But stopping them could ... is mounting. , In the human breast, up to ... originate in stem cells. Now scientists from the Icelandic Cancer ... grown three-dimensional breast cell cultures to reveal unexpected subtleties about ...
... regenerate damaged renal cells in an animal model of ... this inherited kidney disease and offers the first example ... basement membrane matrix defects and restoring organ function. ... Center (BIDMC), the findings are described in the Proceedings ...
... biologists have with wolverines in the Pacific Northwest is seeing ... wildlife biologist Keith Aubry recently got the call he had ... his research team called from a site high in the ... had just been captured. Aubry, a carnivore expert and research ...
Cached Biology News:Clues to breast cancer hidden inside stem cells 2New research demonstrates bone-marrow derived stem cells can reverse genetic kidney disease 2First wolverine radio-collared in Pacific Northwest 2
Insect Cell Lysis Buffer 50 ml...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
AK6 Antibody...
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
Biology Products: